Lewis Kevan G, Dufresne Raymond G
Department of Dermatology, Brown Medical School/Rhode Island Hospital, Providence, Rhode Island 02903, USA.
Dermatol Surg. 2008 Feb;34(2):160-4; discussion 164-5. doi: 10.1111/j.1524-4725.2007.34033.x. Epub 2007 Dec 17.
The frequency of postoperative bleeding and other complications in anticoagulated patients undergoing cutaneous surgery has not been firmly established and consensus on perioperative continuation of treatment is lacking.
The objective was to ascertain the risk of postoperative complications through meta-analysis of data pooled from previously published studies.
A PubMed search (1966-2005) was performed to identify controlled studies reporting bleeding and other complications among patients undergoing cutaneous surgery who were taking anticoagulant medications. Emphasis was placed on prescription anticoagulant medications (aspirin, NSAIDs, warfarin, clopidogrel) and over-the-counter herbal agents with anticoagulant properties.
A total of six studies representing 1,373 patients met criteria for inclusion. Among patients taking aspirin or warfarin, 1.3 and 5.7% experienced a severe postoperative complication, respectively. Patients taking warfarin were nearly seven times as likely to have a moderate-to-severe complication compared to controls (OR, 6.69; 95% CI, 3.03-14.7), a statistically significant difference (p<.001). Patients taking aspirin or NSAIDs were more than twice as likely to have a moderate-to-severe complication compared to controls (OR, 2.0; 95% CI, 0.97-4.13), a strong trend toward statistical significance (p=.06). There were no studies in the literature that examined the effects of combination anticoagulant therapy or the effect of herbal agents on postoperative risk of bleeding.
The results of this meta-analysis suggest that while low, the risk of bleeding among anticoagulated patients may be higher than baseline. Adequately powered prospective studies are required to more carefully delineate the risk of postoperative bleeding and other complications attributable to anticoagulation therapy. Particular emphasis should be placed on examining the effect of combination anticoagulant therapy as well as herbal agents with anticoagulant properties on risk of bleeding after cutaneous surgery.
接受皮肤外科手术的抗凝患者术后出血及其他并发症的发生率尚未明确确定,对于围手术期继续治疗也缺乏共识。
通过对先前发表研究汇总数据进行荟萃分析,确定术后并发症的风险。
进行PubMed检索(1966 - 2005年),以识别报告接受抗凝药物治疗的皮肤外科手术患者出血及其他并发症的对照研究。重点关注处方抗凝药物(阿司匹林、非甾体抗炎药、华法林、氯吡格雷)以及具有抗凝特性的非处方草药制剂。
共有6项研究(涉及1373例患者)符合纳入标准。服用阿司匹林或华法林的患者中,分别有1.3%和5.7%发生了严重术后并发症。与对照组相比,服用华法林的患者发生中度至重度并发症的可能性几乎高出7倍(比值比,6.69;95%置信区间,3.03 - 14.7),差异具有统计学意义(p <.001)。与对照组相比,服用阿司匹林或非甾体抗炎药的患者发生中度至重度并发症的可能性高出两倍多(比值比,2.0;95%置信区间,0.97 - 4.13),有显著的统计学趋势(p = 0.06)。文献中没有研究考察联合抗凝治疗的效果或草药制剂对术后出血风险的影响。
这项荟萃分析的结果表明,尽管抗凝患者出血风险较低,但可能高于基线水平。需要开展有足够效力的前瞻性研究,以更仔细地界定抗凝治疗所致术后出血及其他并发症的风险。应特别强调考察联合抗凝治疗以及具有抗凝特性的草药制剂对皮肤外科手术后出血风险的影响。